Skip to main content
. 2019 Nov 27;38(5):395–405. doi: 10.1200/JCO.19.01638

FIG 2.

FIG 2.

Waterfall plots of change from baseline in tumor size and prostate-specific antigen (PSA) level. (A) Best percentage change from baseline in the sum of longest diameters of target lesions as assessed by RECIST v1.1 by central review in the 199 patients enrolled in cohorts 1 and 2. Asterisks represent the 23 patients in cohort 1 and 10 patients in cohort 2 who were not evaluable for change from baseline in tumor size because they did not have one or more evaluable postbaseline imaging assessment. (B) Best percentage change from baseline in PSA level in the 243 patients enrolled in cohorts 1, 2, and 3 who had a baseline PSA measurement. Asterisks represent the 27 patients in cohort 1, 12 patients in cohort 2, and 11 patients in cohort 3 who had a baseline PSA measurement but did not have one or more postbaseline PSA measurement. Changes > +100% were truncated at +100%.